This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel Forman, MD; Jeanne Y. Wei, MD
Harvard Medical School Boston, Mass

JAMA. 1992;267(9):1209.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We fully agree with Dr Belmin that the lag time between clinical research and the generalized application to medical practice is common to all age groups. Belmin also observed that the percentage of patients receiving β-blockers relative to all patients with myocardial infarction without contraindications did not change with age. Still, the absolute number of elderly patients older than 65 years who might benefit from β-blockade (those without contraindications) was actually higher than that of patients younger than 65 years. Moreover, in light of the high morbidity and mortality associated with myocardial infarction in the elderly,¹ the addition of β-blocker therapy may be especially important. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?